1. Home
  2. MLYS vs FAX Comparison

MLYS vs FAX Comparison

Compare MLYS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.26

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo abrdn Asia-Pacific Income Fund Inc.

FAX

abrdn Asia-Pacific Income Fund Inc.

HOLD

Current Price

$14.53

Market Cap

589.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
FAX
Founded
2019
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
589.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MLYS
FAX
Price
$28.26
$14.53
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$48.67
N/A
AVG Volume (30 Days)
1.3M
199.6K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
12.09%
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.44
$14.18
52 Week High
$47.65
$16.95

Technical Indicators

Market Signals
Indicator
MLYS
FAX
Relative Strength Index (RSI) 57.70 39.38
Support Level $26.85 N/A
Resistance Level $30.53 $15.62
Average True Range (ATR) 1.53 0.27
MACD 0.61 -0.03
Stochastic Oscillator 85.99 27.69

Price Performance

Historical Comparison
MLYS
FAX

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

Share on Social Networks: